Harry Gill Email and Phone Number

Direct the operations of a 7.5 billion dosage / year OTC pharmaceutical solid dosage manufacturing and packaging operation. Key brands managed have included Advil, Caltrate, and Centrum. Responsible for the operational, financial, compliance, and quality performance of the site. Significant accomplishments to date:•Drove Operational Excellence and Engagement program. >$15MM in savings to date.•Increased productivity per person from 7.5MM tablets / person to 10MM tablets / person.•Decreased open investigations by 90%•Improved site First Time Quality from 64 % to >90 %•Implemented competency based training program.•Achieved site VPP Star status from OSHA•Directed the design, installation, and qualification of > $100 million capital site improvements.•Improved Operational Equipment Effectiveness (OEE) from 48% to 63% to date.•2007 FDA inspection result – Site status changed from OAI to VAI

Direct the operations of a 75 MM unit / year OTC pharmaceutical operation. Key brands managed have included Robitussin, Dimetapp, Advil and Children’s Advil. Responsible for the operational, financial, compliance, and quality performance of the factory. Significant accomplishments to date:•Increased productivity per DL operator from 500,000 units / year to 1.4 units million / year•Improved Robitussin cycle time of key product line by 65 % •Improved monthly released to plan metric from 75 % to 95 %•Improved training curriculum completion from 67 % to 95% •Directed the design, installation, and qualification of a $11 million packaging automation plan.•Created a job sharing packaging technician program resulting in $2.4MM cost savings to date.•Factory launched an average of five new SKU’s / year – all launches on schedule or early.•2003 and 2006 FDA inspection result – Zero FD-483 observations•Site Leader of Diversity program – Finalist for 2006 SPHR Diversity Employer All-Star Award

Program Director for top priority R & D program in the Renal Division. Global Development program budget of > 80MM. Responsibilities include resource planning and allocation (40 FTE), expense and capital budget management, schedule development, supplier / consultant contract negotiation, interface with regional and functional management, and program portfolio strategy. Responsible for the program to re – invent the innovation process of the Renal Division. The programs consist of creation and implementation of the “Idea/Concept” evaluation process and for the Portfolio Management Process. Other responsibilities include the leadership of a global latent needs study for Peritoneal Dialysis with IDEO.

Responsible for the establishment and start-up of the Asia Product Development group. Responsible for the development of the Asia Product Development strategy and product portfolio analysis. Responsible for designing and developing new products for the Asian Markets. Co-ordinated efforts between the divisional (U.S.) Product Development groups and the Asia Marketing and Manufacturing teams.

Directed the operation of a 30MM Large Volume Parenteral (LVP) manufacturing facility for Peritoneal Dialysis products supplying the Asian Markets. Responsible for the Operational, Financial, and Quality performance of the facility. Responsible for the management of a 225-person organization. Responsible for managing customer relationships in the Asian Markets including Japan. Significant accomplishments:•Managed plant scale - up. Increased plant output by > 500%•Major supplier to Baxter Asia core business US$ 80MM sales, 50% GP, 20% annual growth•Reduced year to year Asia product cost by 7%•Launched CAPD products for the Japan market•Developed and launched an Asian designed Twinbag. Market share in Korea increased by 9% in 1st year of product life.•Implemented an Operator certification program•Managed the design process of the proposed Plant Expa